Welcome : Guest

Catalyst Biosciences, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Catalyst Biosciences, Inc., which is principally a Clinical-Stage Biopharmaceutical Company. Illustrated with 29 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-65979
Price: $1450
Company Type: Public
Pages: 31
Date: January 2017
Market Data Tables: 29

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Hemophilia......3
Table 1: Hemophilia Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Hemophilia A, Hemophilia B, Inhibitor, and Von Willebrand Disease......3
Table 2: Hemophilia Diagnosis and Treatments Rates by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for Diagonised, Pristine Joints, Prophylactic, Treated, and Others......4
Table 3: Haemophilia by Severity Stage Worldwide (2015) - Percentage Market Share Breakdown by No. of Patients for Mild, Moderate and Severe......5
Table 4: Haemophilia Patient Population by Category Worldwide (2015) - Percentage Market Share Breakdown by Volume for Haemophilia A (Factor VIII Deficiency) and Haemophilia B (Factor IX Deficiency)......6
Table 5: Continuous Prophylaxis (Moderate) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......7
Table 6: Continuous Prophylaxis Treatment (Severe) for Hemophilia A Patients by Age Group Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......8
Table 7: On-Demand (Moderate Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......9
Table 8: On-Demand (Severe Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......10
Table 9: Immune Tolerance Therapy (Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......11
Table 10: Intermittent Prophylaxis (Moderate Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......12
Table 11: Intermittent Prophylaxis (Severe Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......13
Table 12: U.S. Hemophilia Market Patients Treated/Year (2014)......14
Haemophilia B - Recombinant (Benefix)......15
Table 13: Haemophilia B - Recombinant (Benefix) Sales by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Emerging Markets, Europe, US, and Others......15
Anti-Clotting Products......16
Table 14: Anti-Clotting Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Enoxaparin, Fondaparinux, Heparin and Xa inhibitors......16
Factor IX (FIX)......17
Table 15: Factor IX (FIX) Consumption by Category Worldwide (2015) - Percentage Market Share Breakdown by Volume for Plasma-Derived FIX (PD FIX) and Recombinant FIX (r-FIX)......17
Table 16: Factor IX (FIX) Sales by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for Plasma-Derived FIX (PD FIX) and Recombinant FIX (r-FIX)......18
Table 17: Factor IX (FIX) Consumption by Category in the US (2015) - Percentage Market Share Breakdown by Volume for Plasma-Derived FIX (PD FIX) and Recombinant FIX (r-FIX)......19
Table 18: Factor IX (FIX) Sales by Category in the US (2015) - Percentage Market Share Breakdown by Value for Plasma-Derived FIX (PD FIX) and Recombinant FIX (r-FIX)......20
Blindness......21
Table 19: Blindness Market by Category in Germany (2015) - Percentage Market Share Breakdown by Value for Age-Related Macular Degeneration, Cataract, Glaucoma, and Others......21
End-Stage Renal Disease (ESRD)......22
Table 20: End-Stage Renal Disease (ESRD) Cases by Age Group in the US (2015) - Percentage Share Breakdown for 45-64, 65-74, 75+, and Others......22
Table 21: End-Stage Renal Disease (ESRD) Cases by Diagnosis in the US (2015) - Percentage Share Breakdown by Value for Cystic Kidney, Diabetes, Glomerulonephritis, Hypertension, and Others......23
Table 22: End-Stage Renal Disease (ESRD) Market by Cause in China (2015) - Percentage Share Breakdown by Value for Diabetic Nephropathy, Glomerular Disease, Hypertension Caused Renal Disease and Others......24
Speciality Pharmaceuticals......25
Table 23: Speciality Pharmaceuticals Market by Category in the US (2015) - Percentage Share Breakdown by Value Sales for Anti-Coagulant, Growth Hormone, Hepatitis C, HIV/AIDS (incl oral solids), IVIG/Hemophilia, Macular Degeneration, Multiple Sclerosis, Oncology (incl. oral solids), Pulmonary Arterial Hypertension, Renal, Rheumatoid arthritis/Chrohn's, Transplant, and Others......25
Table 24: Specialty Pharmaceuticals Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Hepatitis, HIV & AIDS (including oral solids), Intravenous Immunoglobulin (Hemophilia), Multiple Sclerosis, Oncology (including oral solids), Renal, Rheumatoid Arthritis (Crohn's), and Others......26
Visual Impairment......27
Table 25: Visual Impairment Market by Age Group in Germany (2015) - Percentage Market Share Breakdown by Value for 0-14, 15-49, and 50 and Older......27
Table 26: Visual Impairment Market by Category in Germany (2015) - Percentage Market Share Breakdown by Value for Cataract, Glaucoma, Uncorr Refrerrors, and Others......28
Hemophilia Medicine......29
Table 27: Market Shares of Leading Hemophilia Medicine Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Baxter International, Inc., Bayer AG, CSL Limited, Grifols, S.A., Kedrion S.p.A, Novo Nordisk A/S, Octapharma AG, and Pfizer, Inc.......29
Hemophilia Treatment......30
Table 28: Market Shares of Leading Hemophilia Treatment Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Baxter International, Inc., Bayer AG, CSL Ltd. Novo Nordisk, Pfizer, Inc., and Others......30
Anti-Clotting Products......31
Table 29: Market Shares of Leading Anti-Clotting Brands in the US (2015) - Percentage Market Share Breakdown by Value for Arixtra, Enoxaparin, Fonda. - APO, Heparin, Lovenox, and Xarelto......31